NO783153L - Nytt partikkelmateriale samt fremstilling og anvendelse derav, spesielt som medikament - Google Patents
Nytt partikkelmateriale samt fremstilling og anvendelse derav, spesielt som medikamentInfo
- Publication number
- NO783153L NO783153L NO783153A NO783153A NO783153L NO 783153 L NO783153 L NO 783153L NO 783153 A NO783153 A NO 783153A NO 783153 A NO783153 A NO 783153A NO 783153 L NO783153 L NO 783153L
- Authority
- NO
- Norway
- Prior art keywords
- ganglioside
- particles
- cholera
- hematin
- suspension
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims description 72
- 239000000463 material Substances 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 150000002270 gangliosides Chemical class 0.000 claims description 74
- 229920001282 polysaccharide Polymers 0.000 claims description 62
- 150000004676 glycans Chemical class 0.000 claims description 61
- 239000005017 polysaccharide Substances 0.000 claims description 61
- 102000009016 Cholera Toxin Human genes 0.000 claims description 55
- 108010049048 Cholera Toxin Proteins 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 44
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 claims description 34
- 229940109738 hematin Drugs 0.000 claims description 34
- 239000000725 suspension Substances 0.000 claims description 33
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 30
- 239000011707 mineral Substances 0.000 claims description 30
- 206010008631 Cholera Diseases 0.000 claims description 25
- 239000011236 particulate material Substances 0.000 claims description 25
- 239000003053 toxin Substances 0.000 claims description 20
- 231100000765 toxin Toxicity 0.000 claims description 20
- 108700012359 toxins Proteins 0.000 claims description 20
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 17
- 238000000576 coating method Methods 0.000 claims description 17
- 241000607598 Vibrio Species 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 206010047400 Vibrio infections Diseases 0.000 claims description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 13
- 210000003743 erythrocyte Anatomy 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 6
- 244000052616 bacterial pathogen Species 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- 229920000620 organic polymer Polymers 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 claims 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 2
- 238000010306 acid treatment Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000002421 ganglioside group Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 description 37
- 229920000642 polymer Polymers 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000002504 physiological saline solution Substances 0.000 description 14
- 229920002678 cellulose Polymers 0.000 description 12
- 238000005119 centrifugation Methods 0.000 description 12
- 229920002307 Dextran Polymers 0.000 description 11
- 239000001913 cellulose Substances 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 150000001299 aldehydes Chemical group 0.000 description 7
- -1 amine function ion Chemical class 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000004816 latex Substances 0.000 description 6
- 229920000126 latex Polymers 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 description 5
- 125000003047 N-acetyl group Chemical group 0.000 description 5
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 238000005470 impregnation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 5
- 229910052814 silicon oxide Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229960004279 formaldehyde Drugs 0.000 description 4
- 235000019256 formaldehyde Nutrition 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 150000002148 esters Chemical group 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 229910021426 porous silicon Inorganic materials 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 150000004760 silicates Chemical class 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 2
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Chemical class [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- RJBDSRWGVYNDHL-XNJNKMBASA-N (2S,4R,5S,6S)-2-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2R,3S)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-5-amino-6-[(1S,2R)-2-[(2S,4R,5S,6S)-5-amino-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-4-hydroxyoxane-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)[C@H](O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@@H](CO)O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@H]2O)[C@H](O)[C@H]1O)[C@@H](O)\C=C\CCCCCCCCCCCCC RJBDSRWGVYNDHL-XNJNKMBASA-N 0.000 description 1
- XSHWKULGRFTYIT-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;buta-1,3-diene;styrene Chemical compound C=CC=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C XSHWKULGRFTYIT-UHFFFAOYSA-N 0.000 description 1
- HPILSDOMLLYBQF-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COC(CCC)OCC1CO1 HPILSDOMLLYBQF-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000036632 Brain mass Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 150000003944 halohydrins Chemical class 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JEHCHYAKAXDFKV-UHFFFAOYSA-J lead tetraacetate Chemical compound CC(=O)O[Pb](OC(C)=O)(OC(C)=O)OC(C)=O JEHCHYAKAXDFKV-UHFFFAOYSA-J 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000011146 organic particle Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 150000003138 primary alcohols Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/107—Vibrio
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7728162A FR2403081A1 (fr) | 1977-09-19 | 1977-09-19 | Nouveau materiau particulaire, sa preparation et son application, notamment comme medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO783153L true NO783153L (no) | 1979-03-20 |
Family
ID=9195521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO783153A NO783153L (no) | 1977-09-19 | 1978-09-18 | Nytt partikkelmateriale samt fremstilling og anvendelse derav, spesielt som medikament |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4303638A (ja) |
| JP (1) | JPS5455718A (ja) |
| BE (1) | BE870564A (ja) |
| CH (1) | CH633447A5 (ja) |
| DE (1) | DE2840506A1 (ja) |
| DK (1) | DK411378A (ja) |
| FR (1) | FR2403081A1 (ja) |
| GB (1) | GB2004186B (ja) |
| IT (1) | IT1174425B (ja) |
| NL (1) | NL7809485A (ja) |
| NO (1) | NO783153L (ja) |
| SE (1) | SE7809788L (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0016702B1 (fr) * | 1979-03-16 | 1985-02-20 | Institut Merieux | Médicament, notamment pour le traitement du choléra, et compositions pharmaceutiques le contenant |
| FR2478104B1 (fr) * | 1980-03-17 | 1986-08-08 | Merieux Inst | Nouveaux derives de gangliosides, leur preparation et leur application |
| US4356170A (en) * | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4493825A (en) * | 1982-10-05 | 1985-01-15 | Iowa State University Research Foundation | Purified and antigenically selective vaccines for domestic animals |
| US4507472A (en) * | 1983-06-14 | 1985-03-26 | Usher Thomas C | Manufacture of diethylaminoethyl dextrans |
| IL69558A (en) * | 1983-08-23 | 1988-06-30 | Yeda Res & Dev | Synthetic cholera vaccine |
| US5912017A (en) * | 1987-05-01 | 1999-06-15 | Massachusetts Institute Of Technology | Multiwall polymeric microspheres |
| DD298884A5 (de) * | 1990-07-10 | 1992-03-19 | Charite Der Humboldt-Universitaet,De | Impfstoffe gegen virale antigene und verfahren zu ihrer herstellung |
| DE4141970C2 (de) * | 1991-12-16 | 1998-02-19 | Charite Med Fakultaet | Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung |
| US5380522A (en) * | 1992-08-11 | 1995-01-10 | Day; Charles E. | Method for treatment of irritable bowel syndrome |
| US5502042A (en) * | 1994-07-22 | 1996-03-26 | United States Surgical Corporation | Methods and compositions for treating wounds |
| SE9600648D0 (sv) * | 1996-02-21 | 1996-02-21 | Bror Morein | Receptorbimdande enhet |
| US5943983A (en) * | 1996-08-15 | 1999-08-31 | The United States Of America As Represented By The Secretary Of The Air Force | Non-human primate research support tilt table |
| CA2335487A1 (en) * | 1998-06-19 | 1999-12-23 | Merieux Oravax | Lt and ct in parenteral immunization methods against helicobacter infection |
| WO2006052960A2 (en) * | 2004-11-08 | 2006-05-18 | The General Hospital Corporation | METHODS AND COMPOSITIONS FOR INCREASING STEM CELL HOMING USING Gαs ACTIVATORS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2143088A (en) * | 1937-05-28 | 1939-01-10 | George E Rockwell | Therapeutic agent |
| US2952585A (en) * | 1957-06-19 | 1960-09-13 | New England Inst For Medical R | Immunizing against and treatment of diseases |
| US3185625A (en) * | 1961-11-08 | 1965-05-25 | Brown Ethan Allan | Injectionable substances |
| GB1452648A (en) * | 1973-11-21 | 1976-10-13 | American Home Prod | Cholera toxoid |
| US4125492A (en) * | 1974-05-31 | 1978-11-14 | Pedro Cuatrecasas | Affinity chromatography of vibrio cholerae enterotoxin-ganglioside polysaccharide and the biological effects of ganglioside-containing soluble polymers |
| AR215459A1 (es) * | 1976-04-02 | 1979-10-15 | Brewer J | Metodo para producir un agente terapeutico capaz de proporcionar una marca en un animal no humano para indicar la administracion del agente al animal y para proporcionar tambien un repositorio del agente a ser libeberado durante un espacio de tiempo |
-
1977
- 1977-09-19 FR FR7728162A patent/FR2403081A1/fr active Granted
-
1978
- 1978-09-18 DE DE19782840506 patent/DE2840506A1/de not_active Ceased
- 1978-09-18 GB GB7837186A patent/GB2004186B/en not_active Expired
- 1978-09-18 NO NO783153A patent/NO783153L/no unknown
- 1978-09-18 DK DK411378A patent/DK411378A/da unknown
- 1978-09-18 NL NL7809485A patent/NL7809485A/xx not_active Application Discontinuation
- 1978-09-18 BE BE190555A patent/BE870564A/xx not_active IP Right Cessation
- 1978-09-18 SE SE7809788A patent/SE7809788L/xx unknown
- 1978-09-18 IT IT27801/78A patent/IT1174425B/it active
- 1978-09-18 CH CH970178A patent/CH633447A5/fr not_active IP Right Cessation
- 1978-09-19 JP JP11504578A patent/JPS5455718A/ja active Pending
- 1978-09-19 US US05/944,122 patent/US4303638A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| GB2004186A (en) | 1979-03-28 |
| GB2004186B (en) | 1982-07-14 |
| IT7827801A0 (it) | 1978-09-18 |
| FR2403081A1 (fr) | 1979-04-13 |
| DE2840506A1 (de) | 1979-03-29 |
| US4303638A (en) | 1981-12-01 |
| FR2403081B1 (ja) | 1981-08-21 |
| DK411378A (da) | 1979-03-20 |
| BE870564A (fr) | 1979-03-19 |
| NL7809485A (nl) | 1979-03-21 |
| SE7809788L (sv) | 1979-03-20 |
| CH633447A5 (fr) | 1982-12-15 |
| JPS5455718A (en) | 1979-05-04 |
| IT1174425B (it) | 1987-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO783153L (no) | Nytt partikkelmateriale samt fremstilling og anvendelse derav, spesielt som medikament | |
| US4220717A (en) | Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b. | |
| US4619828A (en) | Polysaccharide exotoxoid conjugate vaccines | |
| CA1210695A (en) | Haemophilus influenzae b polysaccharide exotoxoid conjugate vaccine | |
| NO148250B (no) | Nytt kationisk materiale for reversibel fiksering av biologiske makromolekyler, samt fremstilling og anvendelse av dette | |
| US4308254A (en) | Material able to fix reversibly biologial macromolecules, its preparation and its application | |
| US4459286A (en) | Coupled H. influenzae type B vaccine | |
| US4029762A (en) | Lipid A-preparation | |
| US5410025A (en) | Unmodified intravenously administered immunoglobulin preparations containing immunoglobulin M and/or A | |
| Olofsson et al. | Unusual lectin-binding properties of a herpes simplex virus type 1-specific glycoprotein | |
| Springer et al. | Cross reactive human blood-group H (O) specific polysaccharide from Sassafras albidum and characterization of its hapten | |
| CA1237998A (en) | Method for purification of filamentous hemagglutinin | |
| US4196192A (en) | Combined Haemophilus influenzae type b and pertussis vaccine | |
| EP0527753A1 (en) | CLEANING A PERTUSSIS EXTERIOR MEMBRANE PROTEIN. | |
| US5330975A (en) | Bacterial toxin neutralizer | |
| Klipstein et al. | Immunological interrelationships between cholera toxin and the heat-labile and heat-stable enterotoxins of coliform bacteria | |
| WO2007035341A1 (en) | Protein a production and purification without using animal derived components | |
| Wu-Yuan et al. | Architecture and chemistry of microconidial walls of Trichophyton mentagrophytes | |
| JP2563797B2 (ja) | ボルデテラ属細菌の蛋白質抗原の精製方法 | |
| GB2182937A (en) | Common antigen (psc-a)to pseudomonas aeruginosa | |
| US4001395A (en) | Hydrosoluble extracts of mycobacteria | |
| EP0298991B1 (en) | Novel lectins derived from bacterial pili | |
| JP4091136B2 (ja) | 免疫賦活剤 | |
| CN115161207A (zh) | 半乳糖酵母液的制备方法、半乳糖酵母粉及在亮肤淡化皱纹的应用 | |
| Polotsky et al. | Comparison of conjugates composed of lipopolysaccharide from Shigella flexneri type 2a detoxified by two methods and bound to tetanus toxoid |